Nervous System News and Research

Latest Nervous System News and Research

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.

19 Oct 2010

Study: Gastric function and autonomic nervous system are impaired in obese individuals

Research on obesity examining the role of hormones and the autonomic functions of the digestive system was presented at the 75th Annual Scientific Meeting of the American CoIlege of Gastroenterology.

19 Oct 2010

Survey reveals impact of insomnia during menopause

Results released today from a survey of more than 900 women, who experienced sleep problems during menopause, shed light on the impact insomnia can have during this time in a woman's life. The survey also revealed that for many women, insomnia during menopause is not proactively addressed by their healthcare provider (HCP) and that often times, women don't communicate their symptoms to their HCP.

19 Oct 2010

Vitamin B12 may help protect against Alzheimer's disease

A new study shows that vitamin B12 may protect against Alzheimer's disease, adding more evidence to the scientific debate about whether the vitamin is effective in reducing the risk of memory loss. The research will be published in the October 19, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.

19 Oct 2010

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

Findings from the PRECiSE 3 (P3) open label extension study for Cimzia, demonstrating the longest continuously running maintenance trial for an anti-TNF in Crohn's disease, will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology (ACG), taking place in San Antonio from October 15 – 20. Additionally, long-term efficacy data from the PRECiSE 4 (P4) clinical trial also will be presented at the meeting.

19 Oct 2010

Somaxon announces nonreceipt of Paragraph IV certification for generic Silenor ANDA

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the website of the U.S. Food and Drug Administration (FDA) indicates that an Abbreviated New Drug Application (ANDA) for a generic version of Silenor® (doxepin) 3 mg and 6 mg was submitted on September 16, 2010.

19 Oct 2010

Obese have impaired autonomic function which may lead to overeating

Research on obesity examining the role of hormones and the autonomic functions of the digestive system was presented at the 75th Annual Scientific Meeting of the American CoIlege of Gastroenterology.

18 Oct 2010

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar Therapeutics presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies.

18 Oct 2010

Major advance in treatment of brain disorders with external genes

In the October 17 issue of Nature Methods, researchers at Thomas Jefferson University describe how they can transfer genes into brain neurons intravenously, using a viral gene delivery vehicle (vector) that causes no side effects.

18 Oct 2010

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

Studies and analyses of the Crohn's disease (CD) treatment Cimzia (certolizumab pegol) will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology, taking place in San Antonio from October 15 – 20.

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis. The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

18 Oct 2010

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that data providing further evidence of the neuroprotective properties of laquinimod in animal studies were presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

15 Oct 2010

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Genentech, Inc., a member of the Roche Group, and Biogen Idec today announced 24-week results from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease. Ocrelizumab demonstrated a significant reduction in disease activity as measured by brain lesions and relapse rate.

15 Oct 2010

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Acorda Therapeutics, Inc. today announced that a new analysis of AMPYRA (dalfampridine) Extended Release Tablets, 10 mg data examining walking improvement in treatment responders has been presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2010

UCLA study sheds light on roots of schizophrenia, autism

UCLA scientists have discovered that exposing fetal neurons to higher than normal levels of a common immune protein leads to abnormal brain development in mice.

15 Oct 2010

UCB announces winners of 2010 UCB Crohn's and Me Scholarship Program

UCB, Inc., a global leader in the research and development of medications to treat immunology disorders, today announced the winners of its 2010 UCB Crohn's and Me Scholarship Program for outstanding individuals affected by this condition. UCB has selected 31 winners to receive a scholarship worth up to $10,000 to help them seek personal growth through higher education.

15 Oct 2010

Sanofi-aventis announces TEMSO phase III study results for relapsing multiple sclerosis

Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).

15 Oct 2010

Omeros receives additional NIDA grant for clinical studies in Addiction program

Omeros Corporation today announced that the National Institute on Drug Abuse (NIDA) has provided an additional grant to fund clinical studies for the Company's Addiction program. This grant, which is for a total of approximately $3.6 million to be paid over a four-year period in equal amounts, will fund direct and indirect costs of Phase 2 clinical studies to be conducted by researchers at the New York State Psychiatric Institute.

14 Oct 2010

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

Nervous System News and Research

Latest Nervous System News and Research

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

Study: Gastric function and autonomic nervous system are impaired in obese individuals

Survey reveals impact of insomnia during menopause

Vitamin B12 may help protect against Alzheimer's disease

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

Somaxon announces nonreceipt of Paragraph IV certification for generic Silenor ANDA

Obese have impaired autonomic function which may lead to overeating

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Major advance in treatment of brain disorders with external genes

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

UCLA study sheds light on roots of schizophrenia, autism

UCB announces winners of 2010 UCB Crohn's and Me Scholarship Program

Sanofi-aventis announces TEMSO phase III study results for relapsing multiple sclerosis

Omeros receives additional NIDA grant for clinical studies in Addiction program

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Nervous System News and Research

Latest Nervous System News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in